WilmerHale Advises Xilio Therapeutics In $95M Series C Financing

Download IconDownload Print IconPrint

WilmerHale Advises Xilio Therapeutics In $95M Series C Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On February 24, 2021, Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, announced the successful closing of a $95 million Series C financing round. Proceeds from the financing will be used to advance Xilio’s lead therapeutic candidates, XTX202 (tumor-selective IL-2) and XTX101 (tumor-selective anti-CTLA4 mAb), into clinical trials. The financing was led by Rock Springs Capital and was joined by Bain Capital Life Sciences, Deerfield Management Company and RA Capital Management, among other new investors. Xilio’s existing investors, including Atlas Venture, SV Health Investors, Takeda Ventures, RiverVest Venture Partners, and MRL Ventures Fund, also participated in the financing.

The WilmerHale team representing Xilio Therapeutics was led by Cynthia Mazareas and included Timothy Kulis, Meghan Fay and Elizabeth Brasher.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel